triple negative breast cancer

[Nature Communications] Scientists described a novel multi-kinase inhibitor, 108600, that suppressed growth, colony and mammosphere forming capacity of breast cancer stem cell-like cells and induced G2M arrest and apoptosis of TNBC cells.

[Oncogene] Researchers reported that the expression of CRYβB2 in breast cancer cells increased stemness, growth, and metastasis. Transcriptomics data revealed that CRYβB2 upregulated genes that were functionally associated with unfolded protein response, oxidative phosphorylation, and DNA repair, while down-regulating genes related to apoptosis.

[Carrick Therapeutics (Globe Newswire, Inc.)] Carrick Therapeutics announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.

[Advanced Healthcare Materials] A codelivery strategy that combined the cascaded enzymes lactate oxidase/catalase and vascular endothelial growth factor siRNA to suppress tumor proliferation and angiogenesis synergistically was proposed.

[Immunopharmacology and Immunotoxicology] Scientists determined the effects of indoximod as an indoleamine 2,3-dioxygenase inhibitor on triple-negative breast cancer and to assess the link between the efficacy of indoximod and IFN-γ or TNF-α stimulation.

[Oncogene] Scientists found that DIF-1 induced phosphorylation of AMPK and Raptor and dephosphorylation of p70S6K in multiple TNBC cell lines.